Period:
Draw Mode:
| Volume | 29,091 |
|
|||||
| News | - | ||||||
| Day High | 2.9199 | Low High |
|||||
| Day Low | 2.80 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| PharmaCyte Biotech Inc | PMCB | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.04 | 1.4% | 2.89 | 17:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 2.9199 | 2.80 | 2.9199 | 2.89 | 2.85 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 249 | 29,091 | $ 2.82 | $ 82,011 | - | 1.85 - 3.10 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 17:58:22 | 1 | $ 2.75 | USD |
PharmaCyte Biotech Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 50.41M | 17.44M | 20.67M | $ - | $ - | -0.80 | 9.60 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | 250.00k | 3.40% |
PharmaCyte Biotech News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PMCB Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.84 | 2.99 | 2.78 | 2.89 | 41,850 | 0.05 | 1.76% |
| 1 Month | 2.93 | 3.02 | 2.78 | 2.93 | 36,887 | -0.04 | -1.37% |
| 3 Months | 2.89 | 3.05 | 2.78 | 2.96 | 54,730 | 0.00 | 0.0% |
| 6 Months | 2.49 | 3.10 | 2.34 | 2.85 | 83,375 | 0.40 | 16.06% |
| 1 Year | 2.37 | 3.10 | 1.85 | 2.33 | 195,631 | 0.52 | 21.94% |
| 3 Years | 3.08 | 9.98 | 1.79 | 6.11 | 1,271,176 | -0.19 | -6.17% |
| 5 Years | 3.08 | 9.98 | 1.79 | 6.11 | 1,271,176 | -0.19 | -6.17% |
PharmaCyte Biotech Description
| PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes will be developed. It is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer. |